“…Maintenance therapy should follow because relapse is common, as seen in over half of the patients in the literature review and in one of our two patients. Interestingly, no patients in the literature experienced relapse while on maintenance therapy of azathioprine, sulfasalazine, adalimumab, or infliximab, although the durability of this response is unknown [ 7 , 8 , 10 , 13 , 17 , 19 , 21 ]. There were no reported fatal outcomes.…”